Faeth Therapeutics names Zymeworks R&D head to its board

Faeth Therapeutics (Nasdaq: FTH) has appointed Adam Schayowitz, Ph.D., MBA, to its board of directors, according to a company statement. Dr. Schayowitz currently serves as Executive Vice President and Head of Research and Development at Zymeworks (Nasdaq: ZYME).

Dr. Schayowitz has nearly 20 years of experience in oncology drug development. He previously served as an Operating Partner at EcoR1 Capital and held roles at Pfizer Oncology, most recently as Vice President, Head of Product Development Teams, with oversight across breast cancer, prostate cancer, colorectal cancer, and melanoma programs.

At Tesaro, he led development of Zejula (niraparib), and at Algeta he was part of the Medical Affairs leadership team supporting commercialization of Xofigo (radium-223).

Faeth's lead program, PIKTOR, is an investigational all-oral combination of serabelisib and sapanisertib targeting the PI3K/AKT/mTOR pathway. The company is evaluating PIKTOR in Phase 1b/2 trials for breast cancer and in development for endometrial cancer.

"Adam brings experience in advancing oncology programs from early development through approval and commercialization, including in breast cancer, where we are evaluating PIKTOR in a Phase 1b/2 trial," said Anand Parikh, Co-Founder and Chief Executive Officer of Faeth.

Dr. Schayowitz holds a Ph.D. in Pharmacology and Experimental Therapeutics from the University of Maryland School of Medicine, an MBA from Johns Hopkins University, and a BA from Hamilton College.

You May Also Be Interested In

• Altimmune adds two directors, three to retire ahead of 2027 meeting
• Actuate Therapeutics prices $11M public offering of stock and warrants
• Nexgel regains Nasdaq compliance after minimum bid price fix